Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C | NCT00216775 | Trialant
CompletedObservationalUpdated Sep 2, 2015
Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C
ClinicalTrials.gov ID
NCT00216775
Lead Sponsor
Kyoto UniversityOTHER
Overall Status
Completed
Study Type
Observational
Enrollment
50Actual
Last Update Posted
Sep 2, 2015Estimated
Start Date
Dec 2004
Primary Completion Date
May 2008Actual
Completion Date
May 2008Actual
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of low-dose interferon-alfa-2b plus ribavirin compared to the standard-dose of the same combination in patients with chronic hepatitis C.
Hepatitis C, Chronic
interferon-alfa-2b and ribavirin
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of Chronic Hepatitis C. Must be infected with genotype 1b viruses
Exclusion Criteria:
Hemoglobin levels<8.5g/dL,
Platelet counts<50,000/mm3,
Total polymorphonuclear counts<1000/mm3
Pregnancy,
Renal dysfunction,
Observational Model
Cohort
Time Perspective
Prospective
No central contacts
There are no central contacts for this study.
Department of Gastroenterology and Hepatology, Kyoto University Hospital